Results indicated that the biomarkers present in high concentrations (ApoA1, CRP, and αPGL-I IgM) based on previously obtained ELISA data (van Hooij et al., 2019) distinguished patients with leprosy from controls effectively using 1000-fold dilutions, whereas for detection of IP-10 and S100A12, 10-fold dilutions were required (Figure S1). The gene discussed is APOA1; the disease is leprosy.